Shilpa Medicare has announced that it has received approval from the US health regulator for Irinotecan HCL injection, used for treatment of certain kind of cancers. 

The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials.

Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum.

Shilpa Medicare has been on path of expansion ever since its inception in 1987. With a regulatory recognized manufacturing set up and excellent scientific expert team in place, Shilpa Medicare has since been on a steady growth path. C

Currently it is one of the leaders in the Oncology market and offers a complete range of products in this segment spanning across APIs, formulations both in terms of R&D and manufacturing capabilities. Further to consolidation in field of oncology API and formulations it is striving to put in its efforts in the field of novel drug delivery systems and biotech products along with widening its focus to other therapy areas.